SCHEMBL26987484

SCHEMBL26987484

COC(=O)c1ccnc(Br)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.45
ALDH1A1 P00352 3/20 0.45
GLA P06280 2/20 0.45
GAA P10253 1/20 0.45
PSMD14 O00487 1/20 0.44
ATR Q13535 1/20 0.41
POLB P06746 2/20 0.41
ATM Q13315 1/20 0.41
MAP2K1 Q02750 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
CYP46A1 Q9Y6A2 1/20 0.40
KDM6B O15054 1/20 0.39
KDM5C P41229 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM2A Q9Y2K7 1/20 0.39
KDM3A Q9Y4C1 1/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
SLC6A3 Q01959 1/20 0.38
CFTR P13569 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31184683 1.00 KDM4E (0.45) KDM4EALDH1A1GLAGAAPSMD14
SCHEMBL7259957 0.84 KDM4E (0.46) KDM4EALDH1A1GLAGAAPSMD14
SCHEMBL13041779 0.81 KDM4E (0.47) KDM4EALDH1A1GLAGAAPSMD14
SCHEMBL23500830 0.81 ATR (0.50) KDM4EALDH1A1GLAGAAPSMD14
SCHEMBL20576329 0.81 KDM4E (0.44) KDM4EALDH1A1GLAGAAPSMD14
SCHEMBL27554852 0.79 SMN1; SMN2 (0.38) KDM4EALDH1A1POLBKDM4CTSHR
SCHEMBL112760 0.79 KDM4E (0.44) KDM4EALDH1A1PSMD14TDP1KDM4C
SCHEMBL28608051 0.79 KDM4E (0.42) KDM4EALDH1A1GLAGAAPSMD14
SCHEMBL3553958 0.79 KDM4E (0.53) KDM4EALDH1A1GLAGAAPSMD14
SCHEMBL30950090 0.79 ATR (0.55) KDM4EALDH1A1GLAGAAPSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4551570-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Dong-A ST Co., Ltd. (KR) 2025-05-14 EP disclosed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
WO-2024220626-A1 SMALL MOLECULE MODULATORS OF OGG1 AZKARRA THERAPEUTICS, INC. (US) 2024-10-24 WO disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
WO-2024009215-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR KDM4E 4591/4885ALDH1A1 3927/4885GLA 545/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR KDM4E 4591/4885ALDH1A1 3927/4885GLA 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.